Acrivon Therapeutics Reports A 50% Confirmed Overall Response Rate Observed With ACR-368 In Oncosignature-Positive Gynecological Cancers; Initial Clinical Validation Of AP3 Patient Selection Platform, Demonstrated Ability To Prospectively Predict ACR-368 RECIST Responders
Acrivon Therapeutics 报告称,在 Oncosignature 阳性妇科癌中观察到 ACR-368 的总体缓解率为 50%;AP3 患者选择平台的初步临床验证,显示出前瞻性预测 ACR-368 RECIST 反应者的能力